Financialnewsmedia.com
News Commentary
Palm Beach, FL -- October
31, 2018 -- InvestorsHub NewsWire -- Medicinal cannabis continues
to perform at a high level as its adoption into mainstream markets
continues. Canada and Several states in the United
States are raking in hundreds of millions of dollars in tax
revenues from the raging success of medicinal and recreational
cannabis. According to Statista, medicinal cannabis
revenues could reach as high as $5 Billion in the US
alone by 2020. This past September, the U.S. Drug Enforcement
Administration (DEA) rescheduledsome cannabidiol, a
move that allows the sale of the first nonsynthetic,
cannabis-derived medicine to win federal approval. That decision
came three months after the U.S. Food and Drug Administration
approved Epidiolex, a CBD preparation for rare types of epilepsy
which is a GW Pharmaceuticals plc (NASDAQ:GWPH) lead cannabinoid
product candidate. Active cannabis companies in the markets this
week include Generex Biotechnology Corporation (OTC:GNBT), Canopy
Growth Corporation (NYSE:CGC)
(TSX:WEED), Aurora Cannabis Inc. (NYSE:ACB)
(TSX:ACB), Aphria Inc. (TSX:APH.TO) (OTCQB:APHQF).
Generex
Biotechnology Corporation (OTCQB:GNBT) BREAKING
NEWS: HydRx Farms Ltd. (o/a Scientus Pharma) ("Scientus"
or the "Company"), a biopharmaceutical company conducting research
and product development for extracts and formulations related to
medical cannabinoids and their derivatives, today provided an
update on its collaboration with Generex Biotechnology
Corporation (OTCQB:GNBT) ("Generex"), whereby the
companies are co-developing products for the delivery of
cannabinoids via the buccal mucosa (the inner lining of the
mouth).
Having recently received
Health Canada authorization to produce cannabis softgel capsules
and oils at its state-of-the-art, 45,000 Sq. Ft. commercial
production facility in Whitby, Ontario, the Company will turn
its focus towards the final development of a buccal cannabis spray
using Generex's RapidMistâ„¢ technology.
"The ability to produce
through our proprietary extraction and activation method an
intermediary resin that is >99% activated for THC and CBD allows
us to provide cannabis APIs at scale that can be incorporated into
a variety of delivery methods, such as buccal spray, that were
previously challenged by suboptimal potency and/or
bioavailability," said Har Grover, Chairman and CEO of
Scientus. "Our collaboration with Generex provides access to the
drug delivery technology that will enable development of an
effective cannabis buccal spray. This route of administration is an
attractive alternative to patients who have concerns about inhaling
or eating medical cannabis, but still want its full therapeutic
benefit."
"The RapidMist Buccal
Delivery System from Generex is perfectly suited to the formulation
and administration of cannabinoids for therapeutic benefit",
said Joe Moscato, CEO of Generex. "THC and CBD ratios can be
formulated specifically for therapeutic indications to achieve
optimal benefit, and the device provides a consistent, reliable
metered dose to ensure proper use. Patients will be satisfied with
the ease of use and reliability of effect of the RapidMist Cannabis
product line."Read this and more news
for Generex
Biotechnology at: http://www.financialnewsmedia.com/news-gnbt
Other recent
developments in the cannabis industry
include and companies on
watch:
Canopy Growth
Corporation (NYSE:CGC) (TSX:WEED) recently announced
the launch of a new brand for the recreational market
in Canada, LBS (pronounced "L-B-S"). The Company has
established a curated and world-recognized family of brands, both
in-house and through partnerships with icons in the cannabis space.
LBS is the latest exciting addition to join the family. The LBS
brand slogan -- "Worth Its Weight In Gold" -- is a reference to the
care and quality put into the brand's products and also to its
roots in California , the Golden State. The company name
is also a nod to the shorthand for pounds. In addition to
positioning itself as the gold standard in the cannabis industry,
LBS will focus on embracing diversity and inclusiveness throughout
all brand messaging and Company initiatives. LBS will offer a wide
variety of cannabis strains and products, including flower,
softgels, oil, and pre-rolls, that will be available in select
stores across Canada as of October 17,
2018.
Aurora Cannabis
Inc. (NYSE:ACB) (TSX:ACB) recently announced that
Polish Ministry of Health granted the Company approval for its
first shipment of medical cannabis to Poland. In the coming
days, Aurora Deutschland GmbH will ship the products to a pain
treatment center and a hospital in Warsaw. This is an
important milestone for medical patients in Poland, as it is
believed to be the first time a non-government run business has
been granted approval to supply medical cannabis products in the
country. Under Polish legislation, physicians can prescribe medical
cannabis products to patients who can then access it through
registered pharmacies. In specific instances, products will be
covered under statutory health insurance, thus establishing a new
and significant medical market for Aurora. "Becoming the first
company to supply cannabis to Poland is validation of
Aurora's ability to do business in international markets with high
barriers to entry," said Neil Belot, Chief Global Business
Development Officer. "This is an important milestone for patient
access in Poland, which will provide options for people
seeking alternative medications to help manage symptoms of a wide
range of medical conditions. Aurora continues to grow its
international footprint, which now spans 19 countries on five
continents, and puts us in an enviable position to capitalize on
our early mover advantage."
GW Pharmaceuticals
plc (NASDAQ:GWPH) recently announced the closing of
the previously announced underwritten public offering on the Nasdaq
Global Market by GW of 1,900,000 American Depositary Shares
("ADSs") and the full exercise by the underwriters of their option
to purchase 285,000 additional ADSs from GW at a price to the
public of $158.00 per ADS, raising gross proceeds
of $345,230,000 (before deducting underwriting discounts,
commissions and offering expenses). Goldman Sachs & Co. LLC,
Morgan Stanley & Co. LLC, J.P. Morgan and Cowen and Company,
LLC acted as joint book-running managers for the offering. The ADSs
described above were offered by GW pursuant to a shelf registration
statement filed by GW with the Securities and Exchange Commission
("SEC") that became automatically effective on April 17, 2017.
A prospectus supplement related to the offering has been filed with
the SEC and is available on the SEC's website at http://www.sec.gov .
Aphria
Inc. (TSX:APH.TO) (OTCQB:APHQF) announced that its
common shares have been approved for listing on the New York Stock
Exchange ("NYSE") and will commence trading effective the open of
markets on November 2, 2018. Aphria's shares will trade on the
NYSE under ticker symbol "APHA". The Company's ticker symbol on the
Toronto Stock Exchange (TSX) will also change from "APH" to "APHA",
effective November 2, 2018. Existing shares of Aphria, which
previously traded on the OTCQB under the ticker symbol "APHQF" will
now trade on the NYSE.
DISCLAIMER: FN Media
Group LLC (FNM), which owns and operates Financialnewsmedia.com and
MarketNewsUpdates.com, is a third party publisher and news
dissemination service provider, which disseminates electronic
information through multiple online media channels. FNM is NOT
affiliated in any manner with any company mentioned herein. FNM and
its affiliated companies are a news dissemination solutions
provider and are NOT a registered broker/dealer/analyst/adviser,
holds no investment licenses and may NOT sell, offer to sell or
offer to buy any security. FNM's market updates, news alerts
and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is
intended to be strictly informational and is NEVER to be construed
or interpreted as research material. All readers are strongly urged
to perform research and due diligence on their own and consult a
licensed financial professional before considering any level of
investing in stocks. All material included herein is
republished content and details which were previously disseminated
by the companies mentioned in this release. FNM is not liable
for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. For current services
performed FNM has been compensated forty nine hundred
dollars for news coverage of the current press releases issued
by Generex Biotechnology Corporation by the company. FNM HOLDS NO
SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and FNM undertakes no
obligation to update such statements.
Media
Contact:
editor@financialnewsmedia.com
+1(561)325-8757
SOURCE
FinancialNewsMedia.com
Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Apr 2023 to Apr 2024